Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Kaplan Meier survival curves showed no difference in survival between ablation and surgery {(median: 68 days (range: 0-1550) vs. 107 days (0-1511), respectively (P = 0.662)}. When only dogs surviving the first 21 days (T 21 ) after ablation or surgery were evaluated, the significance in survival was borderline {79 days (45-1550) vs. 250 days (80-1511), respectively, P = 0.082}. None of the parameters measured were associated with survival advantage. Intra-treatment-group survival analysis identified survival advantage for chemotherapy within the surgical group (P = 0.021), this became insignificant (P = 0.430) in T 21 . When the latter were evaluated, Ht >36% (P = 0.016) and white cell count <15.0 9 10 9 /L at presentation (P = 0.021) were associated with an improved outcome. Ht <36% at presentation for all dogs and T 21 showed a significant hazard ratio (0.960, P = 0.037 and 0.947, P = 0.022 respectively).